LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular is supported by durable double-digit organic growth, with 1Q26 revenue of $66.6 million rising 11% reported and 10% organically, driven by 8% pricing and 2% volume despite a soft quarter in distribution. The outlook is further strengthened by improving profitability, as gross margin expanded 350 bps to 72.7%, adjusted EBITDA reached $20.3 million, and FY/26 adjusted EPS guidance was lifted to $2.93-$3.08 with operating margin now expected near 29%. Management’s expanding international footprint, Artegraft’s 36% growth and $10 million 2026 sales goal, plus $367.2 million in cash and short-term marketable securities, suggest meaningful operating leverage, pricing power, and financial flexibility.

LeMaitre Vascular is facing a cautious outlook because its growth depends heavily on areas with execution risk, including a sales force that only reached 158 at the end of 1Q and is expected to rise to 170-180 at YE26, plus a limited pool of suitable M&A targets that could constrain future sales expansion. International exposure also adds uncertainty, since sales outside the U.S. have represented 40% of total revenues in the past and the company still lacks assurance that it will obtain or maintain MDR CE marks for existing products under the EU’s evolving rules through December 2027 and December 2028 for certain classifications. Although 1Q revenue rose 11% to $66.6 million and free cash flow improved to $12.3 million, manufacturing, tissue processing, and regulatory compliance risks could still pressure operating results and limit sustained upside.